Immuno-oncology's evolution: Implications for pharma market researchers
In association with PMGroup
Immuno-oncology therapies that harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. Until recently only a few products had reached the market for a limited number of indications.
However, over the past 12 months several new products have been approved for a wider range of tumour types and with numerous other products in the pipeline, competition looks set to hot up.
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise. Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy. In this video Director Sue Marett discusses the opportunities and challenges for new immuno-oncology therapies and outlines what these mean for pharma market research.
From promise to practice: immuno-oncology in action
Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically and financially
Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.
Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.
To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.
We spoke to key opinion leaders and payers in the US and EU to find out how the new immunotherapy products are faring clinically and financially.